Merck Presents New Data Examining Durable Efficacy with Investigational Cladribine Tablets in Multiple Sclerosis
Phase III studies highlight lasting reductions in relapse rates for an additional two years following short oral treatment courses in year one & year two with Cladribine Tablets
- 16.09.2016, 15:18
- Kategoria: Zdrowie i styl życia
- Źródło: PR Newswire